Hh pathway gene status.
Exons covering the open reading frame of mouse and human SMO/Smo, in addition to exon15 of PTCH1, were PCR-amplified from genomic DNA using a pair of nested primers. The internal pair of primers used in the amplification contained m13 forward or m13 reverse primer sequences. After PCR, free nucleotides and excess primer were removed using ExoSAP-IT kit (USB); PCR products were sequenced in both directions using m13 sequencing primers. PCR products were cycle-sequenced using BigTerminator Kit (Applied Biosystems). All sequencing products were resolved on a 3730xl sequencing machine (Applied Biosystems). Sequence trace files were analyzed using Sequencher (GeneCodes) and/or Mutation Surveyor (SoftGenetics LLC). The SMO D473H mutation was additionally confirmed by primer extension and MALDI-TOF mass spectroscopy of the amplified DNA (MassARRAY, Sequenom, San Diego, California) .
The following primers were utilized; Extend Primer (UEP.D473H): TCAGCTGCCACTTCTAC (5081.3 Da), Analyte G: TCAGCTGCCACTTCTACG (5368.5 Da), Analyte C: TCAGCTGCCACTTCTACC (5328.5 Da). The SMO D473H mutation was previously reported as a rare SNP (ref SNP ID: rs17710891), however we were unable to confirm this genotype in DNA obtained from the affected individual or their pedigree.
Deep sequencing. The region surrounding the SMO exon 8 mutational site was PCR amplified from the primary disease biopsy DNA, metastatic disease biopsy DNA and a control normal DNA (Promega, WI), pooled and analyzed on an Illumina Genome Analyzer. A sequence barcode 'AACGCA' for the primary disease DNA, 'AACTGC' for metastatic disease DNA and 'AAGCCT' for normal DNA was added as part of the PCR process and this sequence was used to sort the sequences into the three categories post sequencing. A total of 57 million 36-bp reads covering the target region was analyzed for the presence of the mutated allele (G>C). We successfully aligned 93.5% of the short reads to the target, requiring a perfect match to one of the three sequence barcodes, and allowing for two mismatches after masking the position of the mutant allele. Alignments were performed using MAQ with the default criteria for filtering poor quality alignments (s1). Analysis was restricted to bases having a quality score ≥ 30, and at each position, the proportion of reads containing variant alleles was computed. The mutant G>C allele of interest occurred in 0.029% of the reads in the primary samples (out of 11.2 million reads with quality ≥ 30), 0.02% in the metastatic sample (out of 13.7 million reads), and 0.02% in the normal sample (out of 10.2 million reads). Using the barcode region and the sequence outside of the position of interest we estimated the background sequencing error rate to be 0.02%, which represents the threshold of detection using this technology. A binomial test (p~0) excludes the presence of the mutant allele at a 0.1% or higher level in any of the samples.
Luciferase reporter assays. C3H10T1/2 cells (ATCC, cat. # CCL-226) were seeded into six-well plates at 1.5 x 10 5 cells/well in DMEM High Glucose with 4 mM glutamine, 10 mM Hepes pH 7.2 and 10% FBS the afternoon before transfection. Cells were transfected the next morning with 400 ng of expression construct, 400 ng of Gli-BS and 200 ng of pRL-TK per well using GeneJuice Transfection Reagent (Novagen, cat. # 70967). For the PTCH1 inhibition experiments, cells were transfected with an additional 200 ng of DNA containing varying ratios of PTCH1 to eGFP expression constructs. Six hours later, cells were collected by trypsin treatment and each well was redistributed over four wells of a 12-well plate. The FBS content of the culture medium was reduced to 0.5% the following morning to induce formation of primary cilia, and small molecule Hh inhibitors were added at indicated concentrations. Luciferase activity was determined 48 hours later with the Dual-Glo Luciferase Assay System (Promega, cat. # E2940). Values were divided by Renilla luciferase activities to normalize for transfection efficiency and are shown as the mean of three separate experiments ± 1 standard deviation.
Western Blot and FACS for expression of Smo and Flag in 10T1/2 cells
10T1/2 cells were transiently transfected using Genejuice Transfection Reagent (Novagen 70967) with either WT Smo, mut Smo, or empty pRK5 vector for 48 hours. Western blot was carried out using standard published methods utilizing a 4-12% Tris-Glycine gel and a nitrocellulose membrane. Protein was detected using the anti-Flag antibody M2 (Sigma F3165) with an Alexa 488 anti-mouse secondary (Molecular Probes A11001). Blots were imaged by fluorescence using an Amersham Biosciences Typhoon Trio. For FACS analysis, transfected cells were dislodged in 1mM EDTA/PBS and subsequently incubated with Smo antibody, 2D11 (1ug/ml), followed by 20 min incubations with biotin-SPconjugated AffiniPure goat anti-mouse IgG (1:100, Jackson Immunoresearch Labs 115-065-071) and R-Phycoerythrin-conjugated Streptavidin (1:50, Jackson
Immunoresearch Labs 016-110-084). After resuspension in PI (500ng/ml), cells were analyzed using a BD Biosciences HTS FacsCalibur.
14 C-GDC-0449 Binding and Competition 293 cells were transiently transfected using Genejuice with either WT Smo or mut Smo for 48 hours. After harvesting in 1mM EDTA in PBS, 10 million cells were fixed with 4%PFA for 10 minutes at room temperature, washed 3X with 1mM EDTA in PBS then incubated for 1 hour at room temperature with 14 C-GDC-0449 (5nM), with or without 50μM cold GDC-0449. Cells were washed 3X with PBS then transferred to a scintillation vial. 15ml PicoFluor 40 was added and counts per minute were assessed using a PerkinElmer liquid scintillation analyzer Tri-Carb 2900TR. All samples were done in triplicate.
Generation of mouse medulloblastoma models of GDC-0449 resistance

Starting at 4 weeks of age, Ptch1
-/+ ;p53 -/-mice on a C57BL/6 background were monitored weekly for the presence of medulloblastomas by MRI. All mice were monitored daily for any signs of abnormal behavior indicative of CNS involvement. Mice with well-defined tumors detected by MRI were sacrificed and tumors dissected from normal cerebellum, mechanically dissociated, and 5 x10 6 cells injected into the lateral thoracic region of CD-1 nude mice (CRL). Tumors were allowed to progress to approximately 400 mm 3 in size at which time mice were treated with 75 mg/kg GDC-0449 (free base equivalents) once daily until tumors decreased in size to approximately 100 mm 3 . Mice were then given a dosing holiday until re-growth occurred. Sequential rounds of treatment and regrowth were applied until the tumors were no longer responsive to daily dosing at which time dosing frequency was increased to twice daily at 75 mg/kg. Resistance developed over a period of 7-10 weeks in these models suggesting that suboptimal dosing of GDC-0449 can rapidly lead to resistance. Tumors that failed to respond to this dose and frequency were then harvested for molecular analysis and passaged (first passage) subcutaneously into additional mice for expansion. In order to analyze pathway modulation in response to GDC-0449, tumor-bearing mice at second-passage were dosed once with 75 mg/kg GDC-0449 and harvested 6 hours post dose for analysis. All mice were housed and maintained according to the animal use guidelines of Genentech, Inc, conforming to California State legal and ethical practices.
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primary MB biopsy biopsy after relapse control Suppl. Fig. 1. The presence and loss of heterozygosity (LOH) of the pre-existing PTCH1 W844C mutation is confirmed in the biopsy taken at relapse. (A) Nucleotide sequence tracings confirm the pre-existing PTCH1 W844C homozygous mutation in a biopsy taken at relapse. (B) Loss of heterozygosity on chromosome 9 in DNA obtained from the biopsy at relapse, as assessed by Affymetrix SNP arrays. Stretches of homozygous allele calls for each SNP probe across the highlighted region of chromosome 9 are shown. Suppl. Fig. 3 . No SMO copy number alterations were detected by qPCR using 2 independent assays from gDNA derived from the biopsy at progression. Copy number was determined by qPCR and calibrated to normal human genomic DNA following normalization to LINE-1. As controls, gDNA from cell lines with low-level copy number changes at the SMO locus, as determined previously by Affymetrix 100K array profiling (predicted), were utilized. 
AA AB BB
